Patents Examined by Nita M. Minnifield
  • Antibodies that neutralize botulinum neurotoxins
    Patent number: 10927165
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: February 23, 2021
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Jianlong Lou
  • Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
    Patent number: 10919946
    Abstract: The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: February 16, 2021
    Assignee: Consejo Superior de Investigaciones Científicas
    Inventors: Maria del Carmen Thomas Carazo, Manuel Carlos López López, Darién Ledesma Arroyo
  • capsular polysaccharides and conjugates thereof
    Patent number: 10918708
    Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: February 16, 2021
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
    Patent number: 10912823
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 9, 2021
    Assignee: Allergan, Inc.
    Inventors: Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • compositions and methods thereof
    Patent number: 10899802
    Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 26, 2021
    Assignee: PFIZER INC.
    Inventors: Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Kathrin Ute Jansen, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
  • Adjuvant for vaccines, vaccine, and immunity induction method
    Patent number: 10857228
    Abstract: The present invention provides an adjuvant for vaccine including a Dectin-1 ligand and a TLR agonist, a vaccine including the adjuvant for vaccine and at least one antigen, and the like.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignee: The University of Tokyo
    Inventors: Satoshi Uematsu, Naoki Takemura
  • Staphylococcal coagulase antigens and methods of their use
    Patent number: 10857220
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: December 8, 2020
    Assignee: The University of Chicago
    Inventors: Molly McAdow, Andrea Dedent, Alice Cheng, Carla Emolo, Dominique Missiakas, Olaf Schneewind
  • Methods of preparing antibodies
    Patent number: 10851138
    Abstract: Disclosed are methods related to the generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases, such as methods of preparing P. gingivalis antibodies, comprising immunizing a non-human animal with a chimeric or fusion protein, wherein the protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 1, 2020
    Assignee: ORAL HEALTH AUSTRALIA PTY LTD
    Inventors: Eric Charles Reynolds, Neil Martin O'Brien Simpson, Keith J Cross, Nada Slakeski
  • AipA, OmpA, and Asp14 in vaccine compositions and diagnostic targets for Anaplasma phagocytophilum infection
    Patent number: 10842860
    Abstract: Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: November 24, 2020
    Assignee: Virginia Commonwealth University
    Inventor: Jason Carlyon
  • Compositions and methods of enhancing immune responses to
    Patent number: 10842858
    Abstract: Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: November 24, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM, THE UNIVERSITY OF GUELPH
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton, Saeed El-Ashram, John Barta, Guillermo Tellez
  • Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
    Patent number: 10835559
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 17, 2020
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Protective anti-ETEC antibody
    Patent number: 10829546
    Abstract: This disclosure relates to an antibody that can protect against ETEC infection in a passive immunization set up. More specifically, it relates to a VHH grafted on an IgA scaffold and produced in plant seeds. When the seeds are given in food or feed, the subject is protected against ETEC infection.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: November 10, 2020
    Assignees: VIB VZW, Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Anna Depicker, Henri De Greve, Vikram Virdi
  • Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
    Patent number: 10828348
    Abstract: Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 10, 2020
    Assignee: Maryland Mental Health Institute, LLC
    Inventors: Eric Finzi, Norman E. Rosenthal
  • Peptides for inducing Chagas disease responses
    Patent number: 10821164
    Abstract: The present disclosure relates to vaccine formulations and their use in treating and preventing Chagas Disease.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: November 3, 2020
    Assignees: Saint Louis University, EPIVAX, INC.
    Inventors: Daniel Hoft, Chris Eickhoff, Annie De Groot
  • Methods for producing multiple recombinant polypeptides in a filamentous fungal host cell
    Patent number: 10822601
    Abstract: The present invention relates to methods for constructing a filamentous fungal strain for production of multiple recombinant polypeptides having biological activity. The present invention also relates to methods for producing multiple recombinant polypeptides having biological activity in a filamentous fungal strain. The present invention also relates to filamentous fungal strains expressing multiple recombinant polypeptides having biological activity.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: November 3, 2020
    Assignee: Novozymes, Inc.
    Inventors: Debbie Yaver, Qiming Jin
  • Pathogen vaccines and methods of producing and using the same
    Patent number: 10813988
    Abstract: The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 27, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Michael Super, Edward J. Doherty, Mark Cartwright, Des White, Alexander G. Stafford, Omar Abdel-Rahman Ali, Amanda Graveline, Donald E. Ingber, David J. Mooney, Benjamin Seiler
  • Methods for the manufacture of proteolytically processed polypeptides
    Patent number: 10808236
    Abstract: The present invention relates to a novel protcolytically active polypeptide and various uses of the polypeptide (and others) in screening and manufacturing methods.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 20, 2020
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventor: Andreas Rummel
  • Yeast-based immunotherapy and type I interferon sensitivity
    Patent number: 10799567
    Abstract: Disclosed are methods of treating individuals with yeast-based immunotherapy who have been preselected as being sensitive to type I interferons, as well as methods for selecting individuals for treatment with yeast-based immunotherapeutic compositions and methods for enhancing or improving an individual's response to yeast-based immunotherapy, based on the individual's sensitivity to type 1 interferons (T1IFNs).
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: October 13, 2020
    Assignees: GlobeImmune, Inc., The Regents of the University of Coloradio
    Inventors: Donald Bellgrau, Thomas H. King
  • Dermal filler
    Patent number: 10792345
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 6, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • High frequency application of botulinum toxin therapy
    Patent number: 10792344
    Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: October 6, 2020
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler